Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
Conforti F, Zucali PA, Pala L, Catania C, Bagnardi V, Sala I, Della Vigna P, Perrino M, Zagami P, Corti C, Stucchi S, Barberis M, Guerini-Rocco E, Di Venosa B, De Vincenzo F, Cordua N, Santoro A, Giaccone G, De Pas TM.
Conforti F, et al. Among authors: di venosa b.
Lancet Oncol. 2022 Oct;23(10):1287-1296. doi: 10.1016/S1470-2045(22)00542-3. Epub 2022 Sep 9.
Lancet Oncol. 2022.
PMID: 36096156
Clinical Trial.
METHODS: CAVEATT was a single-arm, multicentre, phase 2 trial, conducted in two Italian centres (the European Instituteof Oncology and the Humanitas Institute, Milan) in patients with histologically confirmed type B3 thymoma or thymic carcinoma, with advanced stage of dise …
METHODS: CAVEATT was a single-arm, multicentre, phase 2 trial, conducted in two Italian centres (the European Instituteof Oncology an …